1 |
Thiery JP, Acloque H, Huang RY, Nieto MA. 2009. Epithelial-mesenchymal transitions in development and disease. Cell 139: 871-890.
DOI
|
2 |
Zeisberg M, Neilson EG. 2009. Biomarkers for epithelial-mesenchymal transitions. J. Clin. Invest. 119: 1429-1437.
DOI
|
3 |
Chen YC, Shen SC, Lee WR, Lin HY, Ko CH, Shih CM, et al. 2002. Wogonin and fisetin induction of apoptosis through activation of caspase 3 cascade and alternative expression of p21 protein in hepatocellular carcinoma cells SK-HEP-1. Arch. Toxicol. 76: 351-359.
DOI
|
4 |
Zhang Y, Yang H, Sun M, He T, Liu Y, Yang X, et al. 2020. Alpinumisoflavone suppresses hepatocellular carcinoma cell growth and metastasis via NLRP3 inflammasome-mediated pyroptosis. Pharmacol. Rep. 72: 1370-1382.
DOI
|
5 |
Kitamura T, Taketo MM. 2007. Keeping out the bad guys: gateway to cellular target therapy. Cancer Res. 67: 10099-10102.
DOI
|
6 |
Kalluri R, Weinberg RA. 2009. The basics of epithelial-mesenchymal transition. J. Clin. Invest. 119: 1420-1428.
DOI
|
7 |
Xu G, Zhu L, Wang Y, Shi Y, Gong A, Wu C. 2017. Stattic enhances radiosensitivity and reduces radio-induced migration and invasion in HCC cell lines through an apoptosis pathway. Biomed Res. Int. 2017: 1832494.
|
8 |
Weichand B, Popp R, Dziumbla S, Mora J, Strack E, Elwakeel E, et al. 2017. S1PR1 on tumor-associated macrophages promotes lymphangiogenesis and metastasis via NLRP3/IL-1β. J. Exp. Med. 214: 2695-2713.
DOI
|
9 |
Imaeda AB, Watanabe A, Sohail MA, Mahmood S, Mohamadnejad M, Sutterwala FS, et al. 2009. Acetaminophen-induced hepatotoxicity in mice is dependent on Tlr9 and the Nalp3 inflammasome. J. Clin. Invest. 119: 305-314.
DOI
|
10 |
Fan SH, Wang YY, Lu J, Zheng YL, Wu DM, Li MQ, et al. 2014. Luteoloside suppresses proliferation and metastasis of hepatocellular carcinoma cells by inhibition of NLRP3 inflammasome. PLoS One 9: e89961.
DOI
|
11 |
Wang H, Luo Q, Feng X, Zhang R, Li J, Chen F. 2018. NLRP3 promotes tumor growth and metastasis in human oral squamous cell carcinoma. BMC Cancer 18: 500.
DOI
|
12 |
Shao X, Lei Z, Zhou C. 2020. NLRP3 promotes colorectal cancer cell proliferation and metastasis via regulating epithelial mesenchymal transformation. Anticancer Agents Med. Chem. 20: 820-827.
DOI
|
13 |
Deng Q, Geng Y, Zhao L, Li R, Zhang Z, Li K, et al. 2019. NLRP3 inflammasomes in macrophages drive colorectal cancer metastasis to the liver. Cancer Lett. 442: 21-30.
DOI
|
14 |
Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: the next generation. Cell 144: 646-674.
DOI
|
15 |
Saitoh M. 2018. Involvement of partial EMT in cancer progression. J. Biochem. 164: 257-264.
DOI
|
16 |
Wree A, Eguchi A, McGeough MD, Pena CA, Johnson CD, Canbay A, et al. 2014. NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice. Hepatology 59: 898-910.
DOI
|
17 |
Wan L, Yuan X, Liu M, Xue B. 2018. miRNA-223-3p regulates NLRP3 to promote apoptosis and inhibit proliferation of hep3B cells. Exp. Ther. Med. 15: 2429-2435.
|
18 |
Zhou T, Xiang DK, Li SN, Yang LH, Gao LF, Feng C. 2018. MicroRNA-495 ameliorates cardiac microvascular endothelial cell injury and inflammatory reaction by suppressing the NLRP3 inflammasome signaling pathway. Cell. Physiol. Biochem. 49: 798-815.
DOI
|
19 |
Xue L, Lu B, Gao B, Shi Y, Xu J, Yang R, et al. 2019. NLRP3 promotes glioma cell proliferation and invasion via the interleukin-1β/ NF-κB p65 signals. Oncol. Res. 27: 557-564.
DOI
|
20 |
Zhang L, Li H, Zang Y, Wang F. 2019. NLRP3 inflammasome inactivation driven by miR-223-3p reduces tumor growth and increases anticancer immunity in breast cancer. Mol. Med. Rep. 19: 2180-2188.
|
21 |
Karki R, Man SM, Kanneganti TD. 2017. Inflammasomes and cancer. Cancer Immunol. Res. 5: 94-99.
DOI
|
22 |
Shaima'a Hamarsheh RZ. 2020. NLRP3 inflammasome activation in cancer: a double-edged sword. Front. Immunol. 11: 1444.
DOI
|
23 |
Tian X, Zhang S, Zhang Q, Kang L, Ma C, Feng L, et al. 2020. Resveratrol inhibits tumor progression by down-regulation of NLRP3 in renal cell carcinoma. J. Nutr. Biochem. 85: 108489.
DOI
|
24 |
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. 2018. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68: 394-424.
DOI
|
25 |
Eun JR, Jung YJ, Zhang Y, Zhang YH, Tschudyseney B, Ramsamooj R, et al. 2014. Hepatoma SK Hep-1 cells exhibit characteristics of oncogenic mesenchymal stem cells with highly metastatic capacity. PLoS One 9: 110744.
|
26 |
Latz E. 2010. The inflammasomes: mechanisms of activation and function. Curr. Opin. Immunol. 22: 28-33.
DOI
|
27 |
Balogh J, Victor III D, Asham EH, Burroughs SG, Boktour M, Saharia A, et al. 2016. Hepatocellular carcinoma: a review. J. Hepatocell. Carcinoma 3: 41-53.
DOI
|
28 |
Lee HE, Lee JY, Yang G, Kang HC, Cho YY, Lee HS, et al. 2019. Inhibition of NLRP3 inflammasome in tumor microenvironment leads to suppression of metastatic potential of cancer cells. Sci. Rep. 9: 1-9.
DOI
|
29 |
Moossavi M, Parsamanesh N, Bahrami A, Atkin SL, Sahebkar A. 2018. Role of the NLRP3 inflammasome in cancer. Mol. Cancer 17: 158.
DOI
|
30 |
Wei Q, Mu K, Li T, Zhang Y, Yang Z, Jia X, et al. 2014. Deregulation of the NLRP3 inflammasome in hepatic parenchymal cells during liver cancer progression. Lab. Invest. 94: 52-62.
DOI
|
31 |
Ballestar E, Esteller M. 2008. Epigenetic gene regulation in cancer. Adv. Genet. 61: 247-267.
DOI
|
32 |
Hui AM, Makuuchi M, Li X. 1998. Cell cycle regulators and human hepatocarcinogenesis. Hepatogastroenterology 45: 1635-1642.
|
33 |
Diepenbruck M, Christofori G. 2016. Epithelial-mesenchymal transition (EMT) and metastasis: yes, no, maybe?. Curr. Opin. Cell Biol. 43: 7-13.
DOI
|
34 |
Wan S, Meyer AS, Weiler SME, Rupp C, Toth M, Sticht C, et al. 2018. Cytoplasmic localization of the cell polarity factor scribble supports liver tumor formation and tumor cell invasiveness. Hepatology 67: 1842-1856.
DOI
|